USMLE Prep - Medical Reference Library

Peritoneal Dialysis — Modality Selection & Complications

System: Nephrology • Reviewed: Aug 31, 2025 • Step 1Step 2Step 3

Synopsis:

Peritoneal dialysis modality selection considers lifestyle and residual renal function; prevent and treat peritonitis; manage catheter and exit‑site care meticulously.

Key Points

  • Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
  • Use system-specific risk tools to guide testing and disposition.
  • Order high-yield tests first; escalate imaging when indicated.
  • Start evidence-based initial therapy and reassess frequently.

Algorithm

  1. Primary survey and vitals; IV access and monitors.
  2. Focused history/physical; identify red flags and likely etiologies.
  3. Order system-appropriate labs and imaging (see Investigations).
  4. Initiate guideline-based empiric therapy (see Pharmacology).
  5. Reassess response; arrange consultation and definitive management.

Clinical Synopsis & Reasoning

For Peritoneal Dialysis Modality Selection Complications, frame the differential by acuity and pathophysiology, then align diagnostics to the leading hypotheses. Prioritize stabilization while obtaining high‑yield studies such as BMP (Renal/electrolytes), UA ± culture (Hematuria/proteinuria/infection), Renal ultrasound (selected) (Obstruction). Incorporate bedside imaging and targeted labs to define severity and identify complications; synthesize results with clinical trajectory to refine the working diagnosis and disposition needs.


Treatment Strategy & Disposition

Initiate disease‑directed therapy alongside supportive care, titrating to objective response. Pharmacologic options commonly include IV Fluids, Electrolyte repletion. Use validated frameworks (e.g., Peritonitis Empiric Therapy (Examples)) to guide escalation and site of care. Address precipitating factors, de‑escalate empiric therapies with data, and arrange follow‑up for monitoring and risk‑factor modification; admit patients with instability, high risk of deterioration, or needs for close monitoring.


Management Notes

Home support and training quality predict success. Keep a low threshold to culture cloudy effluent.


Epidemiology / Risk Factors

  • CKD/AKI, nephrotoxins; obstruction

Investigations

TestRole / RationaleTypical FindingsNotes
BMPRenal/electrolytesAKI/lyte changes
UA ± cultureHematuria/proteinuria/infectionFindings vary
Renal ultrasound (selected)ObstructionHydronephrosis

Peritonitis Empiric Therapy (Examples)

CoverageRegimen
Gram‑positiveVancomycin or cefazolin IP
Gram‑negativeCeftazidime or aminoglycoside IP
FungalAmphotericin or fluconazole; remove catheter
DurationTypically 2–3 weeks
ProphylaxisExit‑site mupirocin/iodine

Pharmacology

MedicationMechanismOnsetRole in TherapyLimitations
Intraperitoneal vancomycin/cefepimeGlycopeptide/cephHoursEmpiric PD peritonitisNephro/neurotoxicity

Prognosis / Complications

  • Reversibility by cause; electrolyte/volume complications

Patient Education / Counseling

  • Explain red flags and when to seek emergent care.
  • Reinforce medication adherence and follow-up plan.

References

  1. ISPD Peritonitis Guidelines — Link